Our Allucent experts are delighted to be exhibiting at the Fierce Biotech Summit.
We look forward to discussing the latest biotech industry innovations and advancements. Schedule a meeting to discover how our global experience, proven expertise and individualized solutions support small to mid-sized biotechs throughout the clinical development process.
Panel Topic: The Revival of Depression Medication and the Future of Mental Healthcare
10:00am - 10:45am - Wednesday, October 18
Panelist: Marcus Delatte - VP, Regulatory Strategy, Allucent
- Describe the current landscape of depression treatment and understand the challenges and opportunities.
- Tackle the stigma by addressing the importance of a holistic approach and promoting mental health awareness.
- Assess the role of biotech in advancing mental healthcare and accelerating innovation and R&D to meet the growing number of patients.
- Review breakthroughs in depression medication such as personalized medicine in mental healthcare, tailored treatments, novel therapies, and patient outcomes.
- Evaluate the future of mental healthcare by reviewing trends, challenges, and promising directions.
Fellow Panelists:
- Maha Radhakrishnan - Group SVP and Chief Medical Officer, Biogen
- Amit Etkin - Founder and Chief Executive Officer, Alto Neuroscience
- Dr. Laura Gault - Chief Medical Officer, Sage Therapeutics
Fill out the form to schedule a meeting.
.png?width=250&height=249&name=Marcus%20Delatte%20(3).png "Marcus Delatte (3)")
Marcus Delatte
VP, Regulatory Strategy
Marcus served as a Senior Pharmacology/Toxicology Reviewer at the US FDA for 12 years. He is an established expert in translating nonclinical data to inform clinical program design, including dose selection, safety monitoring, inclusion/exclusion criteria for clinical protocols, and informed consent forms. Marcus has extensive experience in creating and implementing strategies for regulatory pathways in the US, as well as preparing and creating strategies for formal FDA meetings.